

Trattamento post-ROSC 2015


Claudio Sandroni

Istituto Anestesiologia e Rianimazione

Università Cattolica del Sacro Cuore - Roma


JAMA® Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial

Theresa M. Olasveengen; Kjetil Sunde; Cathrine Brunborg; et al.




JAMA® Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial


Theresa M. Olasveengen; Kjetil Sunde; Cathrine Brunborg; et al.



Chain of survival



2010.....



Post-rianimazione 2015

- Capitolo nuovo
- Due algoritmi
- In collaborazione con l'European Society of Intensive Care Medicine (ESICM)



European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015
 Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015*



Intensive Care Med
 DOI 10.1007/s00134-015-4051-3

CONFERENCE REPORTS AND EXPERT PANEL



European Resuscitation Council and European Society of Intensive Care Medicine 2015 guidelines for post-resuscitation care


Jerry P. Nolan
 Jasmeet Soar
 Alain Cariou
 Tobias Cronberg
 Véronique R. M. Moulaert
 Charles D. Deakin
 Bernd W. Bottiger
 Hans Friberg
 Kjetil Sunde
 Claudio Sandroni



J.P. Nolan et al. Resuscitation 2015; 95:202–222
 Intensive Care Medicine 2015; *epub ahead of print.*

Algoritmo post-ROSC 2015


Return of spontaneous circulation and comatose




Algoritmo post-rianimazione 2015

Componenti

1. Stabilizzazione immediata
2. Diagnosi e trattamento delle cause
3. Recupero funzionale e prognosi



Return of spontaneous circulation and comatose



1. Stabilizzazione immediata

Return of spontaneous circulation and comatose

Immediate treatment

Airway and breathing

- Maintain SpO_2 94 – 98%
- Insert advanced airway
- Waveform capnography
- Ventilate lungs to normocapnia

Circulation

- 12-lead ECG
- Obtain reliable intravenous access
- Aim for SBP > 100 mmHg
- Fluid (crystalloid) – restore normovolaemia
- Intra-arterial blood pressure monitoring
- Consider vasopressor/ inotrope to maintain SBP

Control temperature

- Constant temperature 32°C – 36°C
- Sedation; control shivering

A, B, C, D (T)


J.P. Nolan et al. Resuscitation 2015; 95:202-22

Intensive Care Medicine 2015; *epub ahead of print.*

Che PaO₂ mantenere?

Air Versus Oxygen in ST-Segment–Elevation Myocardial Infarction

Dion Stub, MBBS, PhD; Karen Smith, BSc, PhD; Stephen Bernard, MBBS, MD;



Association Between Arterial Hyperoxia Following Resuscitation From Cardiac Arrest and In-Hospital Mortality

J. Hope Kilgannon, MD

Alan E. Jones, MD

Nathan I. Shapiro, MD, MPH


Mark G. Angelos, MD

Context Laboratory investigations suggest that exposure to hyperoxia after resuscitation from cardiac arrest may worsen anoxic brain injury; however, clinical data are lacking.

Objective To test the hypothesis that postresuscitation hyperoxia is associated with increased mortality.

Table 4. Outcomes of Study Patients

	All Patients (N = 6326)	Hypoxia (n = 3999)	Normoxia (n = 1171)	Hyperoxia (n = 1156)
In-hospital mortality, No. (%) [95% CI] ^a	3561 (56) [55-58]	2297 (57) [56-59]	532 (45) [43-48]	732 (63) [60-66]
Survivors, No. (%)	2765 (44)	1702 (43)	639 (55)	424 (37)
Independent functional status at hospital discharge, No. (%) [95% CI] ^b	939 (34) [32-36]	570 (33) [31-36]	245 (38) [35-42]	124 (29) [25-34]



Limiti

I risultati non erano stati corretti per FiO₂, gravità della malattia e variabili pre-ospedaliere

Ipo- ed iperossia definite sulla base del primo EGA

Possibile bias selettivo (30% esclusi per la mancanza di EGA)


Arterial hyperoxia and in-hospital mortality after resuscitation from cardiac arrest

Rinaldo Bellomo^{1*}, Michael Bailey¹, Glenn M Eastwood³, Alistair Nichol¹, David Pilcher², Graeme K Hart², Michael C Reade³, Moritoki Egi⁴, D James Cooper¹, the Study of Oxygen in Critical Care (SOCC) Group

- Multicentrico osservazionale, da registro clinico di ICU in Australia
- $n = 11.000$ pazienti rianimati da OHCA
- Outcome primario: mortalità intraospedaliera

Table 6 Multiple regression models for in-hospital mortality and survival time using an APACHE III-based marker of severity^a

Variable	Hospital mortality OR (95% CI)	P value	Time to death HR (95% CI)	P value
AP3no-ox ^b	1.5 (1.5 to 1.6)	<0.0001	1.2 (1.2 to 1.2)	<0.0001
Treatment limitation ^c	5.3 (3.8 to 7.2)	<0.0001	1.7 (1.5 to 1.8)	<0.0001
Year of admission	0.9 (0.9 to 0.9)	<0.0001	0.97 (0.96 to 0.98)	<0.0001
Lowest glucose in first 24 hours	1.1 (1.1 to 1.1)	<0.0001	1.02 (1.02 to 1.03)	<0.0001
Hospital admission from home	1.3 (1.1 to 1.4)	0.0002	1.1 (1.0 to 1.1)	0.02
Hypoxia/poor O ₂ exchange versus normoxia	1.2 (1.1 to 1.4)	0.002	1.1 (1.0 to 1.2)	0.01
Hyperoxia versus normoxia	1.2 (1.0 to 1.5)	0.04	1.1 (1.0 to 1.2)	0.20



Non differenze significative di mortalità tra i differenti livelli di iperossia in confronto alla popolazione di riferimento (pazienti con $83 < \text{PaO}_2 < 93$ mmHg)
 Confermato l'effetto sfavorevole dell'ipossia


ERC Guidelines 2015



- Non appena la saturazione di ossigeno può essere monitorata in modo attendibile (con EGA o pulsiossimetria), regolare la FiO₂ per ottenere una SaO₂ di 94–98%.
- Evitare l'ipossiemia
 - Assicurarsi di avere una misurazione attendibile della SaO₂ prima di ridurre la FiO₂

Che PaCO₂ mantenere?

Association Between Postresuscitation Partial Pressure of Arterial Carbon Dioxide and Neurological Outcome in Patients With Post–Cardiac Arrest Syndrome

Brian W. Roberts, MD; J. Hope Kilgannon, MD; Michael E. Chansky, MD; Neil Mittal, MD; Jonathan Wooden, MD; Stephen Trzeciak, MD, MPH





Clinical paper

Arterial carbon dioxide tension and outcome in patients admitted to the intensive care unit after cardiac arrest[☆]

Antoine G. Schneider^{a,b,1}, Glenn M. Eastwood^{a,1}, Rinaldo Bellomo^{a,b,*}, Michael Bailey^b, Miklos Lipcsey^{a,c}, David Pilcher^d, Paul Young^{e,f}, Peter Stow^g, John Santamaria^h, Edward Stachowskiⁱ, Satoshi Suzuki^a, Nicholas C. Woinarski^a, Janine Pilcher^f

	OR (95% CI)	p-Value	HR (95% CI)	p-Value
Mortality				
Hypo- vs. normocapnia	1.12 (1.00–1.24)	0.04	1.04 (0.98–1.10)	0.24
Hyper- vs. normocapnia	1.15 (0.97–1.35)	0.19	1.04 (0.99–1.09)	0.11
Hyper- vs. hypocapnia	0.95 (0.85–1.06)	0.34	1.00 (0.94–1.07)	0.91
• Mortalità ospedaliera outcome primario				
• Analisi multivariata				
Death OR failure to be discharged home				
Hypo- vs. normocapnia	1.23 (1.00–1.37)	0.03	1.05 (0.99–1.11)	0.06
Hyper- vs. normocapnia	0.97 (0.89–1.06)	0.52	1.00 (0.96–1.05)	0.83
Hyper- vs. hypocapnia	0.99 (0.70–1.28)	0.40	1.00 (0.96–1.01)	0.09

STUDY PROTOCOL

Open Access


A pilot feasibility, safety and biological efficacy multicentre trial of therapeutic hypercapnia after cardiac arrest: study protocol for a randomized controlled trial

Glenn M Eastwood^{1,2,3}, Antoine G Schneider⁴, Satoshi Suzuki⁵, Michael Bailey³, Rinaldo Bellomo^{1,6*},
for the CCC trial investigators

Methods/Design: The CCC trial is a pilot multicentre feasibility, safety and biological efficacy randomized controlled trial recruiting adult cardiac arrest patients admitted to the intensive care unit after return of spontaneous circulation. At admission, using concealed allocation, participants are randomized to 24 h of either normocapnia (PaCO_2 35 to 45 mmHg) or mild hypercapnia (PaCO_2 50 to 55 mmHg). Key feasibility outcomes are recruitment rate and protocol compliance rate. The primary biological efficacy and biological safety measures are the between-groups difference in serum neuron-specific enolase and S100b protein levels at 24 h, 48 h and 72 h. Secondary outcome measure include adverse events, in-hospital mortality, and neurological assessment at 6 months.


ERC Guidelines 2015

- Fino a quando non saranno disponibili dati prospettici, è ragionevole mantenere la normocapnia
 - Monitorare la CO₂ con la ETCO₂ e l'EGA
 - L'ipotermia può ridurre la produzione di CO₂ e causare ipocapnia durante il TTM



2. Diagnosi e trattamento delle cause

% Cause di morte dopo arresto cardiaco



Diagnosis






Table 2. Predictive Values of ST-Segment Elevation for Significant Coronary Lesion and PCI


n = 310


ST-Segment Elevation Predictive Values	Significant Coronary Lesion	Significant PCI
Positive predictive value	0.96	0.74
Specificity	0.95	0.83

Quadro ECG post-ROSC e TIMI










Raccomandazioni EAPCI

- Nei pazienti in arresto cardiaco extraospedaliero
 - Coronarografia immediata se ↑ST all'ECG
 - Coronarografia rapida (<2 ore) negli altri casi se
 - Non c'è causa non-coronarica evidente
 - Paziente emodinamicamente instabile

Diagnosis



Optimising recovery

ICU management

- Temperature control: constant temperature 32°C – 36°C for ≥ 24 h; prevent fever for at least 72 h
- Maintain normoxia and normocapnia; protective ventilation
- Optimise haemodynamics (MAP, lactate, ScvO₂, CO/Cl, urine output)
- Echocardiography
- Maintain normoglycaemia
- Diagnose/treat seizures (EEG, sedation, anticonvulsants)
- Delay prognostication for at least 72 h

Secondary prevention
e.g. ICD, screen for inherited disorders, risk factor management

Follow-up and rehabilitation

3. Recupero funzionale e prognosi

ICU management

- Temperature control: constant temperature 32°C – 36°C for ≥ 24h; prevent fever for at least 72 h
- Maintain normoxia and normocapnia; protective ventilation
- Optimise haemodynamics (MAP, lactate, ScvO₂, CO/Cl, urine output)
- Echocardiography
- Maintain normoglycaemia
- Diagnose/treat seizures (EEG, sedation, anticonvulsants)
- Delay prognostication for at least 72 h

Secondary prevention

e.g. ICD, screen for inherited disorders, risk factor management

Follow-up and rehabilitation

ORIGINAL ARTICLE

Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest

Niklas Nielsen, M.D., Ph.D., Jørn Wetterslev, M.D., Ph.D., Tobias Cronberg, M.D., Ph.D.,
David Erlinge, M.D., Ph.D., Yvan Gasche, M.D., Christian Hassager, M.D., D.M.Sci.,
Janneke Horn, M.D., Ph.D., Jan Hovdenes, M.D., Ph.D.,
Jesper Kjaergaard, M.D., D.M.Sci., Michael Kuiper, M.D., Ph.D., Tommaso Pellis, M.D.,
Pascal Stammet, M.D., Michael Wanscher, M.D., Ph.D., Matt P. Wise, M.D., D.Phil.,
Anders Åneman, M.D., Ph.D., Nawaf Al-Subaie, M.D.,
Søren Boesgaard, M.D., D.M.Sci., John Bro-Jeppesen, M.D., Iole Brunetti, M.D.,
Jan Frederik Bugge, M.D., Ph.D., Christopher D. Hingston, M.D.,
Nicole P. Juffermans, M.D., Ph.D., Matty Koopmans, R.N., M.Sc.,
Lars Køber, M.D., D.M.Sci., Jørund Langørgen, M.D., Gisela Lilja, O.T.,
Jacob Eifer Møller, M.D., D.M.Sci., Malin Rundgren, M.D., Ph.D.,
Christian Rylander, M.D., Ph.D., Ondrej Smid, M.D., Christophe Werer, M.D.,
Per Winkel, M.D., D.M.Sci., and Hans Friberg, M.D., Ph.D.,
for the TTM Trial Investigators*



Esito neurologico TTM trial

Variable	33°C Group	36°C Group
CPC at follow-up†		
Total no. of patients	469	464
Category — no. (%)		
Good	195 (42)	183 (39)
Good	23 (5)	39 (8)
Poor	17 (4)	20 (4)
	6 (1)	2 (0.5)
	228 (49)	220 (47)
P value for trend		0.85

† = at 180±14 days


ICU management

- Temperature control: constant temperature 32°C – 36°C for ≥ 24h; prevent fever for at least 72 h
- Maintain normoxia and normocapnia; protective ventilation
- Optimise haemodynamics (MAP, lactate, ScvO₂, CO/Cl, urine output)
- Echocardiography
- Maintain normoglycaemia
- Diagnose/treat seizures (EEG, sedation, anticonvulsants) (highlighted)
- Delay prognostication for at least 72 h

Secondary prevention

e.g. ICD, screen for inherited disorders, risk factor management

Follow-up and rehabilitation



Clinical Paper

The frequency and timing of epileptiform activity on continuous electroencephalogram in comatose post-cardiac arrest syndrome patients treated with therapeutic hypothermia^{☆,☆☆}

Ram Mani^a, Sarah E. Schmitt^a, Maryann Mazer^b, Mary E. Putt^{c,d}, David F. Gaiseski^{e,f,*}

Clinical Paper

Prognostic value of electrographic postanoxic status epilepticus in comatose cardiac-arrest survivors in the therapeutic hypothermia era[☆]

Stéphane Legriel^{a,*}, Julia Hilly-Ginoux^a, Matthieu Resche-Rigon^b, Sybille Merceron^a, Jeanne Pinoteau^a,

- Fino al 25%-30% dei pazienti in coma dopo ACC presenta attività epilettica all'EEG
- Lo stato di male epilettico postanossico ha un esito sfavorevole nel >90% dei casi

EEG intermittente o continuo?


RESEARCH

Open Access

Yield of intermittent versus continuous EEG in comatose survivors of cardiac arrest treated with hypothermia

Vincent Alvarez¹, Alba Sierra-Marcos¹, Mauro Oddo² and Andrea O Rossetti^{1*}

- Comparazione tra cEEG e 2 tracciati da 20 minuti estratti dal cEEG (“sEEG”)
- 34 tracciati analizzati
- Concordanza cEEG/sEEG:
 - 97% per discontinuità e reattività
 - 94% per attività epilettica



Clinical Paper

Value analysis of continuous EEG in patients during therapeutic hypothermia after cardiac arrest[☆]

Amy Z. Crepeau ^{a,b,g,*}, Jennifer E. Fugate ^{a,c,1}, Jay Mandrekar ^{d,1}, Roger D. White ^{e,f,1},
Eelco F. Wijdicks ^{a,c,1}, Alejandro A. Rabinstein ^{a,c,1}, Jeffrey W. Britton ^{a,b,1}


- Controllo storico tra 91 pazienti con EEG intermittente vs. 62 con cEEG
- 5/62 (8%) convulsioni individuate con cEEG vs. 2/91 (2%)
- Costo \$ 4214 vs. \$ 1571 per paziente
- Nessuna differenza di prognosi

TELSTAR: Treatment of ELectroencephalographic STatus epilepticus After cardiopulmonary Resuscitation

- PI: Jeannette Hofmeijer (Twente, NL)
- Pazienti: in coma dopo arresto cardiaco con stato epilettico
- Comparazione: trattamento farmacologico (3 step) vs. nessun trattamento
- Outcome measure: esito neurologico

Prognosi

% Cause di morte dopo arresto cardiaco



Morte da causa neurologica

- Rappresenta il 40-66% delle morti nei pazienti ricoverati dopo arresto extraospedaliero
- Prevale dopo i primi 3-4 giorni dal ROSC
- Dovuta principalmente a sospensione dei trattamenti

Laver S and Nolan JP Intensive Care Med 2004; 30:2126–2128
Lemiale V et al, Intensive Care Med 2013; 39: 1972–80
Nielsen N et al, N Engl J Med 2013; 369:2197-2206

Previsione del danno neurologico

- Utile per:
 - Informare correttamente i familiari
 - Valutare la prosecuzione dei trattamenti
- Va effettuata ad almeno 72 ore
 - Alcuni test possono essere effettuati prima
- Escludere le interferenze

Arresto cardiaco



Giorni
1-2




Temperatura controllata

Riscaldamento

Giorni
3-5

Magnetic Resonance Imaging (MRI)



Escludere interferenze, specie sedazione residua

Paziente incosciente, M=1-2 a ≥ 72 h dopo ROSC

- Uno o entrambi :
- Pupillari + corneali assenti
 - N20 dei SSEP bilateralmente assente

Sì

Esito sfavorevole
molto probabile
(FPR <5%, 95%CI stretti)

No

Attendere almeno 24h

- Due o più dei seguenti
- Stato mioclonico ≤ 48 h dal ROSC
 - Livelli elevati di NSE
 - EEG areagente con burst-suppression o stato epilettico
 - Danno diffuso su base anossica alla TAC/RMN cerebrale

Sì

Esito sfavorevole
probabile

No

Esito indeterminato
Osserva e rivaluta

Usare più di una metodica ogni volta che è possibile

Conclusioni

- Il trattamento post-rianimatorio è essenziale per il successo della rianimazione
- 3 fasi:
 - Stabilizzazione iniziale
 - Trattamento della causa
 - Recupero funzionale e prognosi
- È importante sapere quando è necessario sospendere i trattamenti

Grazie dell'attenzione!

sandroni@rm.unicatt.it



